nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—CYP1A2—Imiquimod—skin cancer	0.376	0.452	CbGbCtD
Phenylpropanolamine—CYP1A2—Vemurafenib—skin cancer	0.206	0.247	CbGbCtD
Phenylpropanolamine—CYP1A2—Dacarbazine—skin cancer	0.158	0.19	CbGbCtD
Phenylpropanolamine—CYP1A2—Fluorouracil—skin cancer	0.0925	0.111	CbGbCtD
Phenylpropanolamine—DRD1—nerve—skin cancer	0.00591	0.127	CbGeAlD
Phenylpropanolamine—SLC6A3—nerve—skin cancer	0.00475	0.102	CbGeAlD
Phenylpropanolamine—SLC6A2—nerve—skin cancer	0.00383	0.0821	CbGeAlD
Phenylpropanolamine—MAOA—nerve—skin cancer	0.00353	0.0757	CbGeAlD
Phenylpropanolamine—Liver injury—Temozolomide—skin cancer	0.00331	0.0275	CcSEcCtD
Phenylpropanolamine—Irritability—Imiquimod—skin cancer	0.00322	0.0268	CcSEcCtD
Phenylpropanolamine—Urinary retention—Imiquimod—skin cancer	0.0032	0.0266	CcSEcCtD
Phenylpropanolamine—Coordination abnormal—Temozolomide—skin cancer	0.00283	0.0236	CcSEcCtD
Phenylpropanolamine—Constipation—Vismodegib—skin cancer	0.00269	0.0224	CcSEcCtD
Phenylpropanolamine—Euphoric mood—Fluorouracil—skin cancer	0.0022	0.0183	CcSEcCtD
Phenylpropanolamine—Flushing—Imiquimod—skin cancer	0.00216	0.018	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Imiquimod—skin cancer	0.00208	0.0173	CcSEcCtD
Phenylpropanolamine—MAOA—nipple—skin cancer	0.002	0.043	CbGeAlD
Phenylpropanolamine—Vomiting—Vismodegib—skin cancer	0.002	0.0166	CcSEcCtD
Phenylpropanolamine—MAOA—neck—skin cancer	0.00198	0.0425	CbGeAlD
Phenylpropanolamine—Rash—Vismodegib—skin cancer	0.00198	0.0165	CcSEcCtD
Phenylpropanolamine—Dermatitis—Vismodegib—skin cancer	0.00198	0.0165	CcSEcCtD
Phenylpropanolamine—Ataxia—Temozolomide—skin cancer	0.0019	0.0158	CcSEcCtD
Phenylpropanolamine—Nausea—Vismodegib—skin cancer	0.00187	0.0155	CcSEcCtD
Phenylpropanolamine—Agitation—Imiquimod—skin cancer	0.00187	0.0155	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Docetaxel—skin cancer	0.00185	0.0154	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Docetaxel—skin cancer	0.00185	0.0154	CcSEcCtD
Phenylpropanolamine—Hypotension—Vemurafenib—skin cancer	0.00181	0.0151	CcSEcCtD
Phenylpropanolamine—ADRB1—connective tissue—skin cancer	0.00181	0.0389	CbGeAlD
Phenylpropanolamine—Irritability—Fluorouracil—skin cancer	0.00178	0.0148	CcSEcCtD
Phenylpropanolamine—Ataxia—Fluorouracil—skin cancer	0.00175	0.0146	CcSEcCtD
Phenylpropanolamine—Anxiety—Imiquimod—skin cancer	0.00172	0.0143	CcSEcCtD
Phenylpropanolamine—CYP1A2—nipple—skin cancer	0.00167	0.0358	CbGeAlD
Phenylpropanolamine—Constipation—Vemurafenib—skin cancer	0.00166	0.0138	CcSEcCtD
Phenylpropanolamine—Tachycardia—Imiquimod—skin cancer	0.00162	0.0134	CcSEcCtD
Phenylpropanolamine—ADRA2A—nipple—skin cancer	0.00154	0.033	CbGeAlD
Phenylpropanolamine—Flushing—Bleomycin—skin cancer	0.00154	0.0128	CcSEcCtD
Phenylpropanolamine—Insomnia—Imiquimod—skin cancer	0.0015	0.0125	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Imiquimod—skin cancer	0.00148	0.0123	CcSEcCtD
Phenylpropanolamine—Somnolence—Imiquimod—skin cancer	0.00147	0.0122	CcSEcCtD
Phenylpropanolamine—Flushing—Dactinomycin—skin cancer	0.00143	0.0119	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Vemurafenib—skin cancer	0.00143	0.0119	CcSEcCtD
Phenylpropanolamine—MAOA—connective tissue—skin cancer	0.00142	0.0305	CbGeAlD
Phenylpropanolamine—DRD1—head—skin cancer	0.0014	0.03	CbGeAlD
Phenylpropanolamine—Hallucination—Temozolomide—skin cancer	0.00139	0.0116	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Imiquimod—skin cancer	0.00136	0.0114	CcSEcCtD
Phenylpropanolamine—ADRA1A—epithelium—skin cancer	0.00136	0.0292	CbGeAlD
Phenylpropanolamine—Flushing—Temozolomide—skin cancer	0.0013	0.0108	CcSEcCtD
Phenylpropanolamine—Dizziness—Vemurafenib—skin cancer	0.00128	0.0107	CcSEcCtD
Phenylpropanolamine—ADRB1—female reproductive system—skin cancer	0.00128	0.0274	CbGeAlD
Phenylpropanolamine—Ataxia—Docetaxel—skin cancer	0.00126	0.0105	CcSEcCtD
Phenylpropanolamine—Vomiting—Vemurafenib—skin cancer	0.00123	0.0103	CcSEcCtD
Phenylpropanolamine—Rash—Vemurafenib—skin cancer	0.00122	0.0102	CcSEcCtD
Phenylpropanolamine—Dermatitis—Vemurafenib—skin cancer	0.00122	0.0102	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Imiquimod—skin cancer	0.00122	0.0101	CcSEcCtD
Phenylpropanolamine—Confusional state—Bleomycin—skin cancer	0.00119	0.00987	CcSEcCtD
Phenylpropanolamine—MAOA—mammalian vulva—skin cancer	0.00117	0.0251	CbGeAlD
Phenylpropanolamine—Nausea—Vemurafenib—skin cancer	0.00115	0.00959	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Fluorouracil—skin cancer	0.00115	0.00956	CcSEcCtD
Phenylpropanolamine—Vision blurred—Temozolomide—skin cancer	0.00115	0.00953	CcSEcCtD
Phenylpropanolamine—Tremor—Temozolomide—skin cancer	0.00114	0.00948	CcSEcCtD
Phenylpropanolamine—SLC6A3—head—skin cancer	0.00113	0.0241	CbGeAlD
Phenylpropanolamine—Agitation—Temozolomide—skin cancer	0.00112	0.00929	CcSEcCtD
Phenylpropanolamine—Hypotension—Bleomycin—skin cancer	0.0011	0.00914	CcSEcCtD
Phenylpropanolamine—Dizziness—Imiquimod—skin cancer	0.0011	0.00911	CcSEcCtD
Phenylpropanolamine—ADRA2A—connective tissue—skin cancer	0.00109	0.0234	CbGeAlD
Phenylpropanolamine—SLC6A2—female reproductive system—skin cancer	0.00109	0.0233	CbGeAlD
Phenylpropanolamine—ADRB1—head—skin cancer	0.00107	0.0229	CbGeAlD
Phenylpropanolamine—Vision blurred—Fluorouracil—skin cancer	0.00106	0.00878	CcSEcCtD
Phenylpropanolamine—Vomiting—Imiquimod—skin cancer	0.00105	0.00876	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Bleomycin—skin cancer	0.00105	0.00872	CcSEcCtD
Phenylpropanolamine—ADRA1A—lymphoid tissue—skin cancer	0.00105	0.0225	CbGeAlD
Phenylpropanolamine—Rash—Imiquimod—skin cancer	0.00104	0.00869	CcSEcCtD
Phenylpropanolamine—Dermatitis—Imiquimod—skin cancer	0.00104	0.00868	CcSEcCtD
Phenylpropanolamine—Anxiety—Temozolomide—skin cancer	0.00103	0.00858	CcSEcCtD
Phenylpropanolamine—MAOA—female reproductive system—skin cancer	0.001	0.0215	CbGeAlD
Phenylpropanolamine—Confusional state—Temozolomide—skin cancer	0.001	0.00832	CcSEcCtD
Phenylpropanolamine—Nausea—Imiquimod—skin cancer	0.000984	0.00818	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Bleomycin—skin cancer	0.00097	0.00806	CcSEcCtD
Phenylpropanolamine—Confusional state—Fluorouracil—skin cancer	0.000922	0.00767	CcSEcCtD
Phenylpropanolamine—SLC6A2—head—skin cancer	0.000909	0.0195	CbGeAlD
Phenylpropanolamine—Feeling abnormal—Dactinomycin—skin cancer	0.000904	0.00752	CcSEcCtD
Phenylpropanolamine—ADRA2A—mammalian vulva—skin cancer	0.000898	0.0192	CbGeAlD
Phenylpropanolamine—Insomnia—Temozolomide—skin cancer	0.000898	0.00747	CcSEcCtD
Phenylpropanolamine—Tachycardia—Fluorouracil—skin cancer	0.000893	0.00742	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Temozolomide—skin cancer	0.000885	0.00736	CcSEcCtD
Phenylpropanolamine—Somnolence—Temozolomide—skin cancer	0.000882	0.00734	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Bleomycin—skin cancer	0.000867	0.00721	CcSEcCtD
Phenylpropanolamine—Flushing—Docetaxel—skin cancer	0.000862	0.00717	CcSEcCtD
Phenylpropanolamine—Hypotension—Fluorouracil—skin cancer	0.000855	0.00711	CcSEcCtD
Phenylpropanolamine—Constipation—Temozolomide—skin cancer	0.000849	0.00706	CcSEcCtD
Phenylpropanolamine—ADRA1A—head—skin cancer	0.000845	0.0181	CbGeAlD
Phenylpropanolamine—MAOA—head—skin cancer	0.000838	0.0179	CbGeAlD
Phenylpropanolamine—Arrhythmia—Docetaxel—skin cancer	0.00083	0.0069	CcSEcCtD
Phenylpropanolamine—Insomnia—Fluorouracil—skin cancer	0.000827	0.00688	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Temozolomide—skin cancer	0.000818	0.0068	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Fluorouracil—skin cancer	0.000815	0.00678	CcSEcCtD
Phenylpropanolamine—Somnolence—Fluorouracil—skin cancer	0.000813	0.00676	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Dactinomycin—skin cancer	0.000809	0.00672	CcSEcCtD
Phenylpropanolamine—ADRA2A—female reproductive system—skin cancer	0.000769	0.0165	CbGeAlD
Phenylpropanolamine—Feeling abnormal—Fluorouracil—skin cancer	0.000754	0.00627	CcSEcCtD
Phenylpropanolamine—Vomiting—Bleomycin—skin cancer	0.000748	0.00622	CcSEcCtD
Phenylpropanolamine—Rash—Bleomycin—skin cancer	0.000742	0.00617	CcSEcCtD
Phenylpropanolamine—Dermatitis—Bleomycin—skin cancer	0.000741	0.00616	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Temozolomide—skin cancer	0.000731	0.00608	CcSEcCtD
Phenylpropanolamine—Nausea—Bleomycin—skin cancer	0.000699	0.00581	CcSEcCtD
Phenylpropanolamine—Vomiting—Dactinomycin—skin cancer	0.000698	0.0058	CcSEcCtD
Phenylpropanolamine—Rash—Dactinomycin—skin cancer	0.000692	0.00575	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Fluorouracil—skin cancer	0.000674	0.0056	CcSEcCtD
Phenylpropanolamine—Confusional state—Docetaxel—skin cancer	0.000666	0.00554	CcSEcCtD
Phenylpropanolamine—Dizziness—Temozolomide—skin cancer	0.000656	0.00546	CcSEcCtD
Phenylpropanolamine—Nausea—Dactinomycin—skin cancer	0.000652	0.00542	CcSEcCtD
Phenylpropanolamine—Tachycardia—Docetaxel—skin cancer	0.000644	0.00536	CcSEcCtD
Phenylpropanolamine—ADRA2A—head—skin cancer	0.000643	0.0138	CbGeAlD
Phenylpropanolamine—SLC6A2—lymph node—skin cancer	0.000637	0.0136	CbGeAlD
Phenylpropanolamine—Vomiting—Temozolomide—skin cancer	0.000631	0.00525	CcSEcCtD
Phenylpropanolamine—Rash—Temozolomide—skin cancer	0.000626	0.0052	CcSEcCtD
Phenylpropanolamine—Dermatitis—Temozolomide—skin cancer	0.000625	0.0052	CcSEcCtD
Phenylpropanolamine—Hypotension—Docetaxel—skin cancer	0.000617	0.00513	CcSEcCtD
Phenylpropanolamine—Dizziness—Fluorouracil—skin cancer	0.000605	0.00503	CcSEcCtD
Phenylpropanolamine—Insomnia—Docetaxel—skin cancer	0.000597	0.00497	CcSEcCtD
Phenylpropanolamine—Nausea—Temozolomide—skin cancer	0.00059	0.0049	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Docetaxel—skin cancer	0.000589	0.00489	CcSEcCtD
Phenylpropanolamine—Somnolence—Docetaxel—skin cancer	0.000587	0.00488	CcSEcCtD
Phenylpropanolamine—MAOA—lymph node—skin cancer	0.000587	0.0126	CbGeAlD
Phenylpropanolamine—Vomiting—Fluorouracil—skin cancer	0.000582	0.00484	CcSEcCtD
Phenylpropanolamine—Rash—Fluorouracil—skin cancer	0.000577	0.0048	CcSEcCtD
Phenylpropanolamine—Dermatitis—Fluorouracil—skin cancer	0.000576	0.00479	CcSEcCtD
Phenylpropanolamine—Constipation—Docetaxel—skin cancer	0.000564	0.00469	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Docetaxel—skin cancer	0.000544	0.00452	CcSEcCtD
Phenylpropanolamine—Nausea—Fluorouracil—skin cancer	0.000543	0.00452	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Docetaxel—skin cancer	0.000486	0.00404	CcSEcCtD
Phenylpropanolamine—ADRA2A—lymph node—skin cancer	0.00045	0.00964	CbGeAlD
Phenylpropanolamine—Dizziness—Docetaxel—skin cancer	0.000437	0.00363	CcSEcCtD
Phenylpropanolamine—Vomiting—Docetaxel—skin cancer	0.00042	0.00349	CcSEcCtD
Phenylpropanolamine—Rash—Docetaxel—skin cancer	0.000416	0.00346	CcSEcCtD
Phenylpropanolamine—Dermatitis—Docetaxel—skin cancer	0.000416	0.00346	CcSEcCtD
Phenylpropanolamine—Nausea—Docetaxel—skin cancer	0.000392	0.00326	CcSEcCtD
Phenylpropanolamine—DRD1—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	8.91e-06	0.0085	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—PTCH2—skin cancer	8.04e-06	0.00767	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	8.01e-06	0.00764	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	7.84e-06	0.00747	CbGpPWpGaD
Phenylpropanolamine—DRD1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	7.64e-06	0.00728	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—PTCH2—skin cancer	7.23e-06	0.00689	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—PTCH2—skin cancer	7.07e-06	0.00674	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	6.86e-06	0.00654	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	6.71e-06	0.0064	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	6.48e-06	0.00618	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	6.02e-06	0.00574	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transmembrane transport of small molecules—SLC12A2—skin cancer	5.89e-06	0.00561	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	5.86e-06	0.00559	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—PTCH2—skin cancer	5.85e-06	0.00558	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—MC1R—skin cancer	5.81e-06	0.00554	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	5.55e-06	0.00529	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—PTCH2—skin cancer	5.44e-06	0.00518	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	5.27e-06	0.00502	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—MC1R—skin cancer	5.23e-06	0.00498	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmembrane transport of small molecules—SLC12A2—skin cancer	5.22e-06	0.00497	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	5.16e-06	0.00492	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	5.15e-06	0.00491	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—MC1R—skin cancer	5.11e-06	0.00487	CbGpPWpGaD
Phenylpropanolamine—DRD1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	5.02e-06	0.00479	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—RHOU—skin cancer	4.99e-06	0.00476	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	4.51e-06	0.0043	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—RHOU—skin cancer	4.49e-06	0.00428	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	4.42e-06	0.00421	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—RHOU—skin cancer	4.39e-06	0.00419	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	4.26e-06	0.00406	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—MC1R—skin cancer	4.23e-06	0.00403	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—SHH—skin cancer	4.14e-06	0.00395	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—PTCH2—skin cancer	4.13e-06	0.00393	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	3.96e-06	0.00378	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—MC1R—skin cancer	3.93e-06	0.00375	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—PTCH1—skin cancer	3.93e-06	0.00374	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—SMO—skin cancer	3.93e-06	0.00374	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—PTGER4—skin cancer	3.82e-06	0.00364	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—CDK4—skin cancer	3.78e-06	0.0036	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—SHH—skin cancer	3.72e-06	0.00355	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—PTCH2—skin cancer	3.71e-06	0.00354	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	3.65e-06	0.00348	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—SHH—skin cancer	3.64e-06	0.00347	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—RHOU—skin cancer	3.63e-06	0.00346	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—PTCH2—skin cancer	3.63e-06	0.00346	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—PTCH1—skin cancer	3.53e-06	0.00337	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—SMO—skin cancer	3.53e-06	0.00337	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—SMO—skin cancer	3.45e-06	0.00329	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—PTCH1—skin cancer	3.45e-06	0.00329	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—PTGER4—skin cancer	3.44e-06	0.00328	CbGpPWpGaD
Phenylpropanolamine—MAOA—Transmission across Chemical Synapses—BRAF—skin cancer	3.4e-06	0.00324	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	3.39e-06	0.00323	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—RHOU—skin cancer	3.37e-06	0.00322	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—PTGER4—skin cancer	3.36e-06	0.00321	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—MC1R—skin cancer	3.29e-06	0.00313	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	3.28e-06	0.00313	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmission across Chemical Synapses—BRAF—skin cancer	3.16e-06	0.00301	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Arachidonic acid metabolism—PTGS2—skin cancer	3.07e-06	0.00292	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—SHH—skin cancer	3.01e-06	0.00287	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PTCH2—skin cancer	3e-06	0.00286	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—MC1R—skin cancer	2.98e-06	0.00284	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—MC1R—skin cancer	2.95e-06	0.00282	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—MC1R—skin cancer	2.89e-06	0.00275	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—PTCH1—skin cancer	2.86e-06	0.00272	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—SMO—skin cancer	2.86e-06	0.00272	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—SHH—skin cancer	2.8e-06	0.00267	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PTCH2—skin cancer	2.79e-06	0.00266	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—PTGER4—skin cancer	2.78e-06	0.00265	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PLIN2—skin cancer	2.77e-06	0.00264	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—AMPK Signaling—TP53—skin cancer	2.75e-06	0.00262	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—MC1R—skin cancer	2.68e-06	0.00256	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—PTCH1—skin cancer	2.65e-06	0.00253	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—SMO—skin cancer	2.65e-06	0.00253	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—MC1R—skin cancer	2.62e-06	0.0025	CbGpPWpGaD
Phenylpropanolamine—MAOA—Neuronal System—BRAF—skin cancer	2.6e-06	0.00248	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—PTGER4—skin cancer	2.58e-06	0.00246	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	2.55e-06	0.00243	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PTCH2—skin cancer	2.44e-06	0.00232	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Neuronal System—BRAF—skin cancer	2.42e-06	0.00231	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—MC1R—skin cancer	2.39e-06	0.00228	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	2.3e-06	0.00219	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—CSPG4—skin cancer	2.24e-06	0.00213	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—MC1R—skin cancer	2.22e-06	0.00212	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	2.2e-06	0.00209	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PTCH2—skin cancer	2.19e-06	0.00209	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—MC1R—skin cancer	2.17e-06	0.00207	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—PTGER4—skin cancer	2.16e-06	0.00206	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PTCH2—skin cancer	2.14e-06	0.00204	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—SHH—skin cancer	2.13e-06	0.00203	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—MC1R—skin cancer	2.02e-06	0.00192	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—PTCH1—skin cancer	2.02e-06	0.00192	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—SMO—skin cancer	2.02e-06	0.00192	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—PTGER4—skin cancer	1.96e-06	0.00187	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—PTGER4—skin cancer	1.94e-06	0.00185	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—SHH—skin cancer	1.91e-06	0.00182	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—PTGER4—skin cancer	1.9e-06	0.00181	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—SHH—skin cancer	1.87e-06	0.00178	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	1.87e-06	0.00178	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PLIN2—skin cancer	1.85e-06	0.00177	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—GLI2—skin cancer	1.85e-06	0.00176	CbGpPWpGaD
Phenylpropanolamine—MAOA—SIDS Susceptibility Pathways—IL6—skin cancer	1.82e-06	0.00174	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—SMO—skin cancer	1.81e-06	0.00173	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—PTCH1—skin cancer	1.81e-06	0.00173	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PTCH2—skin cancer	1.77e-06	0.00169	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—PTCH1—skin cancer	1.77e-06	0.00169	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—SMO—skin cancer	1.77e-06	0.00169	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—PTGER4—skin cancer	1.76e-06	0.00168	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MC1R—skin cancer	1.76e-06	0.00168	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—GLI1—skin cancer	1.74e-06	0.00166	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—PTGER4—skin cancer	1.73e-06	0.00164	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—GLI2—skin cancer	1.66e-06	0.00158	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PTCH2—skin cancer	1.65e-06	0.00157	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SUFU—skin cancer	1.65e-06	0.00157	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—GLI2—skin cancer	1.62e-06	0.00155	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—TP53—skin cancer	1.61e-06	0.00153	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MC1R—skin cancer	1.58e-06	0.00151	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—PTGER4—skin cancer	1.57e-06	0.0015	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—GLI1—skin cancer	1.56e-06	0.00149	CbGpPWpGaD
Phenylpropanolamine—MAOA—Transmission across Chemical Synapses—HRAS—skin cancer	1.56e-06	0.00149	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MC1R—skin cancer	1.55e-06	0.00148	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—SHH—skin cancer	1.55e-06	0.00147	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—GLI1—skin cancer	1.53e-06	0.00146	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—ENO2—skin cancer	1.52e-06	0.00145	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CSPG4—skin cancer	1.49e-06	0.00142	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SUFU—skin cancer	1.48e-06	0.00141	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—IL6—skin cancer	1.47e-06	0.0014	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PTCH1—skin cancer	1.47e-06	0.0014	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—SMO—skin cancer	1.47e-06	0.0014	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—PTGER4—skin cancer	1.46e-06	0.00139	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmission across Chemical Synapses—HRAS—skin cancer	1.45e-06	0.00138	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SUFU—skin cancer	1.45e-06	0.00138	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	1.45e-06	0.00138	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—SHH—skin cancer	1.44e-06	0.00137	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PTGER4—skin cancer	1.43e-06	0.00136	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PTCH1—skin cancer	1.36e-06	0.0013	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—SMO—skin cancer	1.36e-06	0.0013	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—GLI2—skin cancer	1.34e-06	0.00128	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PTGER4—skin cancer	1.33e-06	0.00126	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MC1R—skin cancer	1.28e-06	0.00122	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—GLI1—skin cancer	1.26e-06	0.0012	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SHH—skin cancer	1.26e-06	0.0012	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GLI2—skin cancer	1.25e-06	0.00119	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—RASA1—skin cancer	1.25e-06	0.00119	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	1.25e-06	0.00119	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SUFU—skin cancer	1.2e-06	0.00114	CbGpPWpGaD
Phenylpropanolamine—MAOA—Neuronal System—HRAS—skin cancer	1.2e-06	0.00114	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MC1R—skin cancer	1.19e-06	0.00114	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PTCH1—skin cancer	1.19e-06	0.00114	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SMO—skin cancer	1.19e-06	0.00114	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GLI1—skin cancer	1.17e-06	0.00112	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PTGER4—skin cancer	1.16e-06	0.0011	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SHH—skin cancer	1.13e-06	0.00108	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—RASA1—skin cancer	1.12e-06	0.00107	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SUFU—skin cancer	1.11e-06	0.00106	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Neuronal System—HRAS—skin cancer	1.11e-06	0.00106	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SHH—skin cancer	1.1e-06	0.00105	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—RASA1—skin cancer	1.1e-06	0.00105	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PTCH1—skin cancer	1.07e-06	0.00102	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SMO—skin cancer	1.07e-06	0.00102	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.06e-06	0.00101	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SMO—skin cancer	1.05e-06	0.000998	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PTCH1—skin cancer	1.05e-06	0.000998	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PTGER4—skin cancer	1.04e-06	0.000993	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—FOXO4—skin cancer	1.02e-06	0.000976	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PLIN2—skin cancer	1.02e-06	0.000975	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PTGER4—skin cancer	1.02e-06	0.000972	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ENO2—skin cancer	1.02e-06	0.000968	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.01e-06	0.000967	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—FOXO4—skin cancer	9.2e-07	0.000877	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SHH—skin cancer	9.14e-07	0.000871	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—RASA1—skin cancer	9.08e-07	0.000865	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—FOXO4—skin cancer	9e-07	0.000858	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—ERCC2—skin cancer	8.83e-07	0.000841	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SMO—skin cancer	8.66e-07	0.000826	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PTCH1—skin cancer	8.66e-07	0.000826	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SHH—skin cancer	8.49e-07	0.000809	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—RASA1—skin cancer	8.44e-07	0.000804	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PTGER4—skin cancer	8.43e-07	0.000804	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CSPG4—skin cancer	8.24e-07	0.000786	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SMO—skin cancer	8.05e-07	0.000767	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PTCH1—skin cancer	8.05e-07	0.000767	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PTGER4—skin cancer	7.83e-07	0.000747	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—FOXO4—skin cancer	7.45e-07	0.00071	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—FOXO4—skin cancer	6.92e-07	0.00066	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TERT—skin cancer	6.84e-07	0.000652	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—NRAS—skin cancer	6.79e-07	0.000647	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TERT—skin cancer	6.15e-07	0.000586	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TERT—skin cancer	6.01e-07	0.000573	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ERCC2—skin cancer	5.9e-07	0.000562	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—KRAS—skin cancer	5.84e-07	0.000557	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—NRAS—skin cancer	5.76e-07	0.000549	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ENO2—skin cancer	5.6e-07	0.000534	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—BRAF—skin cancer	5.42e-07	0.000516	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PTGS2—skin cancer	5.29e-07	0.000505	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—TP53—skin cancer	5.19e-07	0.000495	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—NRAS—skin cancer	5.18e-07	0.000494	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—NRAS—skin cancer	5.07e-07	0.000483	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TERT—skin cancer	4.97e-07	0.000474	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—HRAS—skin cancer	4.96e-07	0.000473	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—KRAS—skin cancer	4.96e-07	0.000473	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—BRAF—skin cancer	4.87e-07	0.000464	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—BRAF—skin cancer	4.76e-07	0.000454	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TERT—skin cancer	4.62e-07	0.000441	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—KRAS—skin cancer	4.46e-07	0.000425	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	4.38e-07	0.000418	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—KRAS—skin cancer	4.36e-07	0.000416	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—HRAS—skin cancer	4.21e-07	0.000402	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—NRAS—skin cancer	4.19e-07	0.0004	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—IL6—skin cancer	4.03e-07	0.000385	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—BRAF—skin cancer	3.94e-07	0.000376	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—NRAS—skin cancer	3.89e-07	0.000371	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—HRAS—skin cancer	3.79e-07	0.000361	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—HRAS—skin cancer	3.71e-07	0.000353	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—BRAF—skin cancer	3.66e-07	0.000349	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—IL6—skin cancer	3.63e-07	0.000346	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—KRAS—skin cancer	3.61e-07	0.000344	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—IL6—skin cancer	3.55e-07	0.000338	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PTGS2—skin cancer	3.54e-07	0.000337	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NRAS—skin cancer	3.4e-07	0.000324	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—KRAS—skin cancer	3.35e-07	0.00032	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ERCC2—skin cancer	3.26e-07	0.00031	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—HRAS—skin cancer	3.07e-07	0.000292	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NRAS—skin cancer	3.06e-07	0.000292	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NRAS—skin cancer	2.99e-07	0.000285	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—IL6—skin cancer	2.93e-07	0.00028	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—KRAS—skin cancer	2.93e-07	0.000279	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—HRAS—skin cancer	2.85e-07	0.000272	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL6—skin cancer	2.73e-07	0.00026	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—KRAS—skin cancer	2.63e-07	0.000251	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TP53—skin cancer	2.6e-07	0.000248	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—KRAS—skin cancer	2.58e-07	0.000246	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HRAS—skin cancer	2.49e-07	0.000237	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NRAS—skin cancer	2.48e-07	0.000236	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL6—skin cancer	2.38e-07	0.000227	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TP53—skin cancer	2.34e-07	0.000223	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NRAS—skin cancer	2.3e-07	0.000219	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TP53—skin cancer	2.29e-07	0.000218	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HRAS—skin cancer	2.24e-07	0.000213	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HRAS—skin cancer	2.19e-07	0.000209	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL6—skin cancer	2.14e-07	0.000204	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KRAS—skin cancer	2.13e-07	0.000203	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL6—skin cancer	2.1e-07	0.0002	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KRAS—skin cancer	1.98e-07	0.000189	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTGS2—skin cancer	1.95e-07	0.000186	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TP53—skin cancer	1.89e-07	0.000181	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HRAS—skin cancer	1.81e-07	0.000173	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TP53—skin cancer	1.76e-07	0.000168	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL6—skin cancer	1.73e-07	0.000165	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HRAS—skin cancer	1.68e-07	0.00016	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL6—skin cancer	1.61e-07	0.000154	CbGpPWpGaD
